BCRX Earnings Date: Nov 4, 2026 (Estimated) — BioCryst Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is BCRX's next earnings date?
BioCryst Pharmaceuticals, Inc. (BCRX) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.09 on revenue of $165.7M.
How did BCRX do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), BioCryst Pharmaceuticals, Inc. posted EPS of $0.30 versus the $0.15 estimate, a beat of 36.4%. Revenue was $218.3M against a $183.3M estimate. The stock's 1-day post-earnings move was +0.6%.
How much does BCRX stock move after earnings?
BCRX beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.1% (up or down) in the day after earnings.
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | 0.15 | 0.30 | +36.36% | $218.3M | ✅ Beat | +0.55% | +14.63% | +12.75% |
| 2026-05-06 | Q1 2026 | 0.10 | 0.14 | +40.00% | $156.4M | ✅ Beat | -2.21% | -2.55% | -6.20% |
| 2026-02-26 | Q4 2025 | 0.07 | 0.06 | -21.43% | $163.3M | ❌ Miss | +4.64% | +13.51% | +26.62% |
| 2025-11-03 | Q3 2025 | 0.08 | 0.16 | +100.00% | $159.4M | ✅ Beat | -6.28% | -3.14% | -2.19% |
| 2025-08-04 | Q2 2025 | 0.03 | 0.15 | +400.00% | $163.4M | ✅ Beat | +9.81% | +4.40% | +4.28% |
| 2025-02-24 | Q4 2024 | -0.06 | -0.13 | -116.67% | $131.5M | ❌ Miss | -9.99% | -6.51% | -12.60% |
| 2024-11-04 | Q3 2024 | -0.06 | -0.07 | -16.67% | $117.1M | ❌ Miss | -12.81% | -7.71% | -14.71% |
| 2024-05-06 | Q1 2024 | -0.21 | -0.17 | +19.05% | $92.8M | ✅ Beat | +18.43% | +19.55% | +51.46% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $218.3M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 72.2% | $157.5M | -3.0% | $237.3M | $143.8M | $162.4M | $157.7M |
| License and Other Revenues | 27.8% | $60.7M | — | — | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.